Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. MSTR
7. HOOD
8. ABBV
9. LLY
10. DFTX

Go back to Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)

May 14, 2024 8:47 AM EDT

BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).

The analyst comments "FULC announced the company has entered an exclusive license agreement with Sanofi (ticker: SNY; covered by Graham Perry) for the ex-US development of losmapimod in... More

Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel

May 13, 2024 12:31 PM EDT

Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $22.00 (from $19.00) while maintaining a Buy rating.

The analyst comments "Ph.3 REACH (facioscapulohumeral muscular dystrophy [FSHD]) data in 4Q24 are the main focus for FY2024, and we're... More